Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy
Open Access
- 17 October 2014
- journal article
- research article
- Published by Springer Nature in EJNMMI Research
- Vol. 4 (1) , 58
Abstract
Bone Scan Index (BSI) is a quantitative measurement of tumour burden in the skeleton calculated from bone scan images. When analysed at the time of diagnosis,it has been shown to provide prognostic information on survival in men with metastatic prostate cancer (PCa). In this study, we evaluated the prognostic value of BSI during androgen deprivation therapy (ADT). Prostate cancer patients who were at high risk of a poor outcome and who had undergone bone scan at the time of diagnosis and during ADT were recruited from two university hospitals for a retrospective study. BSI at baseline and follow-up were calculated using an automated software package (EXINIbonebsi).Associations between BSI, other prognostic biomarkers and overall survival (OS)were evaluated using a Cox proportional hazards regression model. One hundred forty-six PCa patients were included in the study. A total of 102patient deaths were registered, with a median survival time after the follow-up bone scan of 2.4 years (interquartile range (IQR) =0.8 to 4.4). Both at baseline and during ADT, BSI was significantly associated with OS in univariate and multivariate analyses. When BSI was added to a prognostic base model including age, prostate-specific antigen, clinical tumour stage and Gleason score, the concordance index increased from 0.73 to 0.77 (p =0.0005) at baseline and from 0.77 to 0.82 (p <0.0001) during ADT. Automated BSI during ADT is an independent prognostic indicator of OS in PCa patients with bone metastasis. It represents an emerging imaging biomarker that can be used in a prognostic model for risk stratification of PCa patients at the time of diagnosis and at later stages of the disease. BSI could then help physicians identify patients who could benefit from more aggressive therapies.Keywords
This publication has 16 references indexed in Scilit:
- Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapyEJNMMI Research, 2013
- Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan indexEJNMMI Research, 2013
- Prediction of survival benefit using an automated bone scan index in patients with castration‐resistant prostate cancerBJU International, 2012
- A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan IndexEuropean Urology, 2012
- High-Risk Prostate Cancer: From Definition to Contemporary ManagementEuropean Urology, 2012
- Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate CancerJournal of Clinical Oncology, 2012
- When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification ToolEuropean Urology, 2010
- A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?Bioinformatics, 2008
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Prognostic Value of Bone Scan in Patients With Metastatic Prostate Cancer Treated Initially With Androgen Deprivation TherapyJournal of Urology, 2002